Free Trial

Renalytix (RENX) Competitors

Renalytix logo
GBX 5.31 -0.13 (-2.30%)
As of 11:20 AM Eastern

RENX vs. KOO, COG, INHC, IQAI, and FDBK

Should you buy Renalytix stock or one of its competitors? Renalytix's main competitors and comparable companies include Kooth (KOO), Cambridge Cognition (COG), Induction Healthcare Group (INHC), IQ-AI (IQAI), and Feedback (FDBK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare technology" industry.

How does Renalytix compare to Kooth?

Kooth (LON:KOO) and Renalytix (LON:RENX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

Kooth has higher revenue and earnings than Renalytix. Renalytix is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kooth£62.02M1.07£4.00M£15.0012.14
Renalytix£3M11.87-£109.93M-£3.00N/A

Kooth has a beta of 1.34, indicating that its share price is 34% more volatile than the broader market. Comparatively, Renalytix has a beta of 1.707, indicating that its share price is 71% more volatile than the broader market.

21.0% of Kooth shares are owned by institutional investors. Comparatively, 14.0% of Renalytix shares are owned by institutional investors. 30.4% of Kooth shares are owned by company insiders. Comparatively, 3.9% of Renalytix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Kooth presently has a consensus target price of GBX 345, indicating a potential upside of 89.40%. Given Kooth's stronger consensus rating and higher probable upside, equities analysts plainly believe Kooth is more favorable than Renalytix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kooth
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Renalytix
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Kooth's average media sentiment score of 0.00 equaled Renalytix'saverage media sentiment score.

Company Overall Sentiment
Kooth Neutral
Renalytix Neutral

Kooth has a net margin of 9.43% compared to Renalytix's net margin of -506.25%. Renalytix's return on equity of 675.00% beat Kooth's return on equity.

Company Net Margins Return on Equity Return on Assets
Kooth9.43% 17.74% 10.12%
Renalytix -506.25%675.00%-93.54%

Summary

Kooth beats Renalytix on 11 of the 14 factors compared between the two stocks.

How does Renalytix compare to Cambridge Cognition?

Renalytix (LON:RENX) and Cambridge Cognition (LON:COG) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

14.0% of Renalytix shares are owned by institutional investors. Comparatively, 13.1% of Cambridge Cognition shares are owned by institutional investors. 3.9% of Renalytix shares are owned by company insiders. Comparatively, 3.3% of Cambridge Cognition shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Renalytix has a beta of 1.707, indicating that its share price is 71% more volatile than the broader market. Comparatively, Cambridge Cognition has a beta of 0.809, indicating that its share price is 19% less volatile than the broader market.

In the previous week, Cambridge Cognition had 1 more articles in the media than Renalytix. MarketBeat recorded 1 mentions for Cambridge Cognition and 0 mentions for Renalytix. Cambridge Cognition's average media sentiment score of 0.38 beat Renalytix's score of 0.00 indicating that Cambridge Cognition is being referred to more favorably in the news media.

Company Overall Sentiment
Renalytix Neutral
Cambridge Cognition Neutral

Cambridge Cognition has a net margin of -13.86% compared to Renalytix's net margin of -506.25%. Renalytix's return on equity of 675.00% beat Cambridge Cognition's return on equity.

Company Net Margins Return on Equity Return on Assets
Renalytix-506.25% 675.00% -93.54%
Cambridge Cognition -13.86%-54.17%-0.30%

Cambridge Cognition has a consensus target price of GBX 56, indicating a potential upside of 101.66%. Given Cambridge Cognition's stronger consensus rating and higher probable upside, analysts clearly believe Cambridge Cognition is more favorable than Renalytix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Renalytix
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Cambridge Cognition
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Cambridge Cognition has higher revenue and earnings than Renalytix. Cambridge Cognition is trading at a lower price-to-earnings ratio than Renalytix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Renalytix£3M11.87-£109.93M-£3.00N/A
Cambridge Cognition£10.13M1.48-£1.58M-£3.10N/A

Summary

Cambridge Cognition beats Renalytix on 9 of the 16 factors compared between the two stocks.

How does Renalytix compare to Induction Healthcare Group?

Induction Healthcare Group (LON:INHC) and Renalytix (LON:RENX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability.

Induction Healthcare Group has a beta of -0.41, indicating that its share price is 141% less volatile than the broader market. Comparatively, Renalytix has a beta of 1.707, indicating that its share price is 71% more volatile than the broader market.

Induction Healthcare Group has higher revenue and earnings than Renalytix. Renalytix is trading at a lower price-to-earnings ratio than Induction Healthcare Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Induction Healthcare Group£12.57M0.72-£5.12M-£5.54N/A
Renalytix£3M11.87-£109.93M-£3.00N/A

In the previous week, Induction Healthcare Group's average media sentiment score of 0.00 equaled Renalytix'saverage media sentiment score.

Company Overall Sentiment
Induction Healthcare Group Neutral
Renalytix Neutral

Induction Healthcare Group has a net margin of -23.86% compared to Renalytix's net margin of -506.25%. Renalytix's return on equity of 675.00% beat Induction Healthcare Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Induction Healthcare Group-23.86% -14.58% -7.32%
Renalytix -506.25%675.00%-93.54%

46.3% of Induction Healthcare Group shares are owned by institutional investors. Comparatively, 14.0% of Renalytix shares are owned by institutional investors. 54.6% of Induction Healthcare Group shares are owned by insiders. Comparatively, 3.9% of Renalytix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Induction Healthcare Group beats Renalytix on 7 of the 11 factors compared between the two stocks.

How does Renalytix compare to IQ-AI?

Renalytix (LON:RENX) and IQ-AI (LON:IQAI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

In the previous week, Renalytix's average media sentiment score of 0.00 equaled IQ-AI'saverage media sentiment score.

Company Overall Sentiment
Renalytix Neutral
IQ-AI Neutral

14.0% of Renalytix shares are owned by institutional investors. 3.9% of Renalytix shares are owned by company insiders. Comparatively, 66.0% of IQ-AI shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

IQ-AI has lower revenue, but higher earnings than Renalytix.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Renalytix£3M11.87-£109.93M-£3.00N/A
IQ-AI£538.19K3.30N/AN/AN/A

IQ-AI has a net margin of -77.52% compared to Renalytix's net margin of -506.25%. Renalytix's return on equity of 675.00% beat IQ-AI's return on equity.

Company Net Margins Return on Equity Return on Assets
Renalytix-506.25% 675.00% -93.54%
IQ-AI -77.52%-140.75%-22.03%

Renalytix has a beta of 1.707, meaning that its stock price is 71% more volatile than the broader market. Comparatively, IQ-AI has a beta of 2.25, meaning that its stock price is 125% more volatile than the broader market.

Summary

Renalytix beats IQ-AI on 5 of the 9 factors compared between the two stocks.

How does Renalytix compare to Feedback?

Feedback (LON:FDBK) and Renalytix (LON:RENX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

Feedback has higher earnings, but lower revenue than Renalytix. Renalytix is trading at a lower price-to-earnings ratio than Feedback, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Feedback£849.62K1.84-£10.84M-£15.74N/A
Renalytix£3M11.87-£109.93M-£3.00N/A

Feedback has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market. Comparatively, Renalytix has a beta of 1.707, suggesting that its stock price is 71% more volatile than the broader market.

31.5% of Feedback shares are owned by institutional investors. Comparatively, 14.0% of Renalytix shares are owned by institutional investors. 8.0% of Feedback shares are owned by insiders. Comparatively, 3.9% of Renalytix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Feedback's average media sentiment score of 0.75 beat Renalytix's score of 0.00 indicating that Feedback is being referred to more favorably in the media.

Company Overall Sentiment
Feedback Positive
Renalytix Neutral

Feedback has a net margin of -446.94% compared to Renalytix's net margin of -506.25%. Renalytix's return on equity of 675.00% beat Feedback's return on equity.

Company Net Margins Return on Equity Return on Assets
Feedback-446.94% -96.66% -22.99%
Renalytix -506.25%675.00%-93.54%

Summary

Feedback beats Renalytix on 7 of the 12 factors compared between the two stocks.

Get Renalytix News Delivered to You Automatically

Sign up to receive the latest news and ratings for RENX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RENX vs. The Competition

MetricRenalytixHealthcare Technology IndustryHealthcare SectorLON Exchange
Market Cap£35.61M£1.98B£7.88B£2.84B
Dividend YieldN/A3.89%2.47%5.11%
P/E Ratio-1.7742.1433.3323.37
Price / Sales11.875.188.125.05
Price / Cash1.8415.7621.0220.23
Price / Book-0.505.794.802.51
Net Income-£109.93M-£19.09M£3.52B£5.88B
7 Day Performance-0.54%-6.15%-4.56%-0.01%
1 Month Performance-0.80%-4.37%-2.78%-2.15%
1 Year Performance-22.30%-11.27%0.12%7.21%

Renalytix Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RENX
Renalytix
N/AGBX 5.31
-2.3%
N/A-20.5%£35.61M£3MN/A102
KOO
Kooth
N/AGBX 184
-0.5%
GBX 345
+87.5%
+41.5%£66.95M£62.02M12.27478
COG
Cambridge Cognition
1.6183 of 5 stars
GBX 30.50
+5.2%
GBX 56
+83.6%
-4.7%£16.46M£10.13MN/A74
INHC
Induction Healthcare Group
N/AGBX 9.75
flat
N/A+0.0%£9.00M£12.57MN/A74
IQAI
IQ-AI
N/AGBX 0.80
flat
N/A+0.0%£1.77M£538.19KN/A6

Related Companies and Tools


This page (LON:RENX) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners